Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Swisher

Showing results (121-130 of 194) with videos related to

Pageof 20
Sort By:
Ebiomedicine|September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Science Translational Medicine|June 21, 2023
<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant <i>BRCA</i>-mutant ovarian cancerNitasha Gupta, Tzu-Ting Huang, Jayakumar R Nair, et al.
American Journal of Obstetrics and Gynecology|June 18, 2025
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II studyTamar A Gootzen, Miranda P Steenbeek, Marleen M H J van Gelder, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
NPJ Precision Oncology|May 18, 2023
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J Gray, Payel Chatterjee, Rachele Rosati, et al.
JMIR Formative Research|September 26, 2022
Using Social Media to Facilitate Communication About Women's Testing: Tool Validation StudyTara Coffin, Deborah Bowen, Karen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Molecular Diagnostics : JMD|June 5, 2012
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencingColin C Pritchard, Christina Smith, Stephen J Salipante, et al.
Blood|May 21, 2026
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotypeJ Philip Creamer, Suhita Ray, Sintra Stewart, et al.
Pageof 20

Showing results (121-130 of 194) with videos related to

Sort By:
Pageof 20
Ebiomedicine|September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Science Translational Medicine|June 21, 2023
<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant <i>BRCA</i>-mutant ovarian cancerNitasha Gupta, Tzu-Ting Huang, Jayakumar R Nair, et al.
American Journal of Obstetrics and Gynecology|June 18, 2025
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II studyTamar A Gootzen, Miranda P Steenbeek, Marleen M H J van Gelder, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
NPJ Precision Oncology|May 18, 2023
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J Gray, Payel Chatterjee, Rachele Rosati, et al.
JMIR Formative Research|September 26, 2022
Using Social Media to Facilitate Communication About Women's Testing: Tool Validation StudyTara Coffin, Deborah Bowen, Karen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II StudyErika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Molecular Diagnostics : JMD|June 5, 2012
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencingColin C Pritchard, Christina Smith, Stephen J Salipante, et al.
Blood|May 21, 2026
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotypeJ Philip Creamer, Suhita Ray, Sintra Stewart, et al.
Pageof 20